<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Imaging</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Imaging</journal-id><journal-title-group><journal-title>Cancer Imaging</journal-title></journal-title-group><issn pub-type="ppub">1740-5025</issn><issn pub-type="epub">1470-7330</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1470-7330-14-S1-P2</article-id><article-id pub-id-type="doi">10.1186/1470-7330-14-S1-P2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Can we save our resources with half-body-18F-FDG-PET-CT rather than whole-body, in the management of head &#x00026; neck cancers?</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Sonoda</surname><given-names>LI</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>luke@sonoda.co.uk</email></contrib><contrib contrib-type="author" id="A2"><name><surname>Lakhani</surname><given-names>A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Ghosh-Ray</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>Paul Strickland Scanner Centre, Mount Vernon Hospital, London, UK</aff><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>9</day><month>10</month><year>2014</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Proceedings of the International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</named-content><named-content content-type="supplement-sponsor">Publication charges for this supplement were funded through the International Cancer Imaging Society by support received from Siemens AG, Healthcare Sector, Imaging and Therapy Division.</named-content></supplement><fpage>P2</fpage><lpage>P2</lpage><permissions><copyright-statement>Copyright &#x000a9; 2014 Sonoda et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Sonoda et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.cancerimagingjournal.com/content/14/S1/P2"/><conference><conf-date>9-11 October 2014</conf-date><conf-name>International Cancer Imaging Society (ICIS) 14th Annual Teaching Course</conf-name><conf-loc>Heidelberg, Germany</conf-loc></conference></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>18F-FDG PET-CT plays a significant role in the management of head and neck (H&#x00026;N) malignancies. There have been recent suggestions that half-body (above diaphragm) PET-CT may be sufficient for the management of H&#x00026;N cancer patients. This study aims to determine if half-body PET-CT is a safe practice option, or should we stick to whole-body PET-CT.</p></sec><sec sec-type="methods"><title>Methods</title><p>A 6-year-period retrospective analysis of 729 consecutive PET-CT scans of H&#x00026;N cancer patients was performed in order to record the incidence of below-diaphragm metastases and below-diaphragm synchronous primary malignancies. The four main indications of PET-CT in H&#x00026;N cancers are; pre-treatment staging of high-risk of disseminated disease, metastatic cervical lymphadenopathy with unknown primary, assessment of therapeutic response and detection of recurrence/relapse.</p></sec><sec sec-type="results"><title>Results</title><p>A total of 664 squamous cell carcinoma (SCC) and 65 nasopharyngeal carcinoma (NPC) cases were studied. 35/729 (4.8%) of cases showed below-diaphragm metastases (liver, renal, adrenal, retroperitoneal and lumbar vertebral metastases), 24/664 (3.3%) by SCC and 11/65 (16.9%) by NPC.</p><p>52/729 (7.1%) cases showed synchronous primary malignancies, of which 32 (4.4%) were below-diaphragm (colonic, pancreatic, bladder cancers and retroperitoneal lymphoma).</p><p>In total, 84/729 (11.5%) H&#x00026;N cases had either below-diaphragm metastases or below-diaphragm synchronous primary malignancies.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>A significant proportion of H&#x00026;N patients, over 10%, have either below-diaphragm metastases or below-diaphragm synchronous primary malignancies. Half-body (above diaphragm) PET-CT would have missed these lesions, leading to mis-staging of disease and mis-management of patients. It is important to keep whole-body PET-CT in practice in the management of H&#x00026;N cancers. This is more so in the management of NPC compared to SCC.</p></sec></body></article>
